BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 19946261)

  • 1. Novel RUNX1 mutations in familial platelet disorder with enhanced risk for acute myeloid leukemia: clues for improved identification of the FPD/AML syndrome.
    Jongmans MC; Kuiper RP; Carmichael CL; Wilkins EJ; Dors N; Carmagnac A; Schouten-van Meeteren AY; Li X; Stankovic M; Kamping E; Bengtsson H; Schoenmakers EF; van Kessel AG; Hoogerbrugge PM; Hahn CN; Brons PP; Scott HS; Hoogerbrugge N
    Leukemia; 2010 Jan; 24(1):242-6. PubMed ID: 19946261
    [No Abstract]   [Full Text] [Related]  

  • 2. A novel RUNX1 mutation in familial platelet disorder with propensity to develop myeloid malignancies.
    Kirito K; Sakoe K; Shinoda D; Takiyama Y; Kaushansky K; Komatsu N
    Haematologica; 2008 Jan; 93(1):155-6. PubMed ID: 18166807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dysmegakaryopoiesis, a clue for an early diagnosis of familial platelet disorder with propensity to acute myeloid leukemia in case of unexplained inherited thrombocytopenia associated with normal-sized platelets.
    Latger-Cannard V; Philippe C; Jonveaux P; Lecompte T; Favier R
    J Pediatr Hematol Oncol; 2011 Oct; 33(7):e264-6. PubMed ID: 21900832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into familial platelet disorder with propensity to myeloid malignancy (FPD/AML).
    Owen C
    Leuk Res; 2010 Feb; 34(2):141-2. PubMed ID: 19695705
    [No Abstract]   [Full Text] [Related]  

  • 5. Haematological spectrum and genotype-phenotype correlations in nine unrelated families with RUNX1 mutations from the French network on inherited platelet disorders.
    Latger-Cannard V; Philippe C; Bouquet A; Baccini V; Alessi MC; Ankri A; Bauters A; Bayart S; Cornillet-Lefebvre P; Daliphard S; Mozziconacci MJ; Renneville A; Ballerini P; Leverger G; Sobol H; Jonveaux P; Preudhomme C; Nurden P; Lecompte T; Favier R
    Orphanet J Rare Dis; 2016 Apr; 11():49. PubMed ID: 27112265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Familial platelet disorder with propensity to acute myelogenous leukemia: genetic heterogeneity and progression to leukemia via acquisition of clonal chromosome anomalies.
    Minelli A; Maserati E; Rossi G; Bernardo ME; De Stefano P; Cecchini MP; Valli R; Albano V; Pierani P; Leszl A; Sainati L; Lo Curto F; Danesino C; Locatelli F; Pasquali F
    Genes Chromosomes Cancer; 2004 Jul; 40(3):165-71. PubMed ID: 15138996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Familial platelet disorder with predisposition to myeloid leukemia (FPD/AML): a case report and literature review].
    Zhang RR; Chen XJ; Ren YY; Yang WY; Zhu XF
    Zhonghua Xue Ye Xue Za Zhi; 2021 Apr; 42(4):308-312. PubMed ID: 33979975
    [No Abstract]   [Full Text] [Related]  

  • 8. Myeloid neoplasms with germ line RUNX1 mutation.
    Hayashi Y; Harada Y; Huang G; Harada H
    Int J Hematol; 2017 Aug; 106(2):183-188. PubMed ID: 28534116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder.
    Preudhomme C; Renneville A; Bourdon V; Philippe N; Roche-Lestienne C; Boissel N; Dhedin N; André JM; Cornillet-Lefebvre P; Baruchel A; Mozziconacci MJ; Sobol H
    Blood; 2009 May; 113(22):5583-7. PubMed ID: 19357396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CBL mutation in chronic myelomonocytic leukemia secondary to familial platelet disorder with propensity to develop acute myeloid leukemia (FPD/AML).
    Shiba N; Hasegawa D; Park MJ; Murata C; Sato-Otsubo A; Ogawa C; Manabe A; Arakawa H; Ogawa S; Hayashi Y
    Blood; 2012 Mar; 119(11):2612-4. PubMed ID: 22138511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical phenotype of germline RUNX1 haploinsufficiency: from point mutations to large genomic deletions.
    Béri-Dexheimer M; Latger-Cannard V; Philippe C; Bonnet C; Chambon P; Roth V; Grégoire MJ; Bordigoni P; Lecompte T; Leheup B; Jonveaux P
    Eur J Hum Genet; 2008 Aug; 16(8):1014-8. PubMed ID: 18478040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired hematopoietic differentiation of RUNX1-mutated induced pluripotent stem cells derived from FPD/AML patients.
    Sakurai M; Kunimoto H; Watanabe N; Fukuchi Y; Yuasa S; Yamazaki S; Nishimura T; Sadahira K; Fukuda K; Okano H; Nakauchi H; Morita Y; Matsumura I; Kudo K; Ito E; Ebihara Y; Tsuji K; Harada Y; Harada H; Okamoto S; Nakajima H
    Leukemia; 2014 Dec; 28(12):2344-54. PubMed ID: 24732596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic basis of myeloid transformation in familial platelet disorder/acute myeloid leukemia patients with haploinsufficient RUNX1 allele.
    Sakurai M; Kasahara H; Yoshida K; Yoshimi A; Kunimoto H; Watanabe N; Shiraishi Y; Chiba K; Tanaka H; Harada Y; Harada H; Kawakita T; Kurokawa M; Miyano S; Takahashi S; Ogawa S; Okamoto S; Nakajima H
    Blood Cancer J; 2016 Feb; 6(2):e392. PubMed ID: 26849013
    [No Abstract]   [Full Text] [Related]  

  • 14. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis.
    Michaud J; Wu F; Osato M; Cottles GM; Yanagida M; Asou N; Shigesada K; Ito Y; Benson KF; Raskind WH; Rossier C; Antonarakis SE; Israels S; McNicol A; Weiss H; Horwitz M; Scott HS
    Blood; 2002 Feb; 99(4):1364-72. PubMed ID: 11830488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent CDC25C mutations drive malignant transformation in FPD/AML.
    Yoshimi A; Toya T; Kawazu M; Ueno T; Tsukamoto A; Iizuka H; Nakagawa M; Nannya Y; Arai S; Harada H; Usuki K; Hayashi Y; Ito E; Kirito K; Nakajima H; Ichikawa M; Mano H; Kurokawa M
    Nat Commun; 2014 Aug; 5():4770. PubMed ID: 25159113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted gene correction of RUNX1 in induced pluripotent stem cells derived from familial platelet disorder with propensity to myeloid malignancy restores normal megakaryopoiesis.
    Iizuka H; Kagoya Y; Kataoka K; Yoshimi A; Miyauchi M; Taoka K; Kumano K; Yamamoto T; Hotta A; Arai S; Kurokawa M
    Exp Hematol; 2015 Oct; 43(10):849-57. PubMed ID: 26021490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AML1/RUNX1 gene point mutations in childhood myeloid malignancies.
    Migas A; Savva N; Mishkova O; Aleinikova OV
    Pediatr Blood Cancer; 2011 Oct; 57(4):583-7. PubMed ID: 21294243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations.
    Harada Y; Harada H
    J Cell Biochem; 2011 Feb; 112(2):425-32. PubMed ID: 21268063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A new form of familial platelet disorder caused by germline mutations in RUNX1 in a pedigree].
    Guan J; Wang LL; Wang CY; Zhu XM; Shuai HZ; Yi X; Zou L; Yu D; Cheng H
    Zhonghua Nei Ke Za Zhi; 2023 Apr; 62(4):393-400. PubMed ID: 37032134
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeted correction of RUNX1 mutation in FPD patient-specific induced pluripotent stem cells rescues megakaryopoietic defects.
    Connelly JP; Kwon EM; Gao Y; Trivedi NS; Elkahloun AG; Horwitz MS; Cheng L; Liu PP
    Blood; 2014 Sep; 124(12):1926-30. PubMed ID: 25114263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.